VSports注册入口 - Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official VSports app下载. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2017 Jan;58(1):117-122.
doi: 10.2967/jnumed.116.178665. Epub 2016 Aug 4.

Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates

Affiliations
Free article

"V体育安卓版" Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates

Nicolas Tournier et al. J Nucl Med. 2017 Jan.
Free article

Abstract

The tyrosine kinase inhibitor erlotinib poorly penetrates the blood-brain barrier (BBB) because of efflux transport by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), thereby limiting its utility in the treatment of non-small cell lung cancer metastases in the brain. Pharmacologic strategies to inhibit ABCB1/ABCG2-mediated efflux transport at the BBB have been successfully developed in rodents, but it remains unclear whether these can be translated to humans given the pronounced species differences in ABCG2/ABCB1 expression ratios at the BBB. We assessed the efficacy of two different ABCB1/ABCG2 inhibitors to enhance brain distribution of 11C-erlotinib in nonhuman primates as a model of the human BBB. VSports手机版.

Methods: Papio anubis baboons underwent PET scans of the brain after intravenous injection of 11C-erlotinib under baseline conditions (n = 4) and during intravenous infusion of high-dose erlotinib (10 mg/kg/h, n = 4) or elacridar (12 mg/kg/h, n = 3) V体育安卓版. .

Results: Under baseline conditions, 11C-erlotinib distribution to the brain (total volume of distribution [VT], 0. 22 ± 0. 015 mL/cm3) was markedly lower than its distribution to muscle tissue surrounding the skull (VT, 0. 86 ± 0. 10 mL/cm3). Elacridar infusion resulted in a 3. 5 ± 0 V体育ios版. 9-fold increase in 11C-erlotinib distribution to the brain (VT, 0. 81 ± 0. 21 mL/cm3, P < 0. 01), reaching levels comparable to those in muscle tissue, without changing 11C-erlotinib plasma pharmacokinetics. During high-dose erlotinib infusion, 11C-erlotinib brain distribution was also significantly (1. 7 ± 0. 2-fold) increased (VT, 0. 38 ± 0. 033 mL/cm3, P < 0. 05), with a concomitant increase in 11C-erlotinib plasma exposure. .

Conclusion: We successfully implemented ABCB1/ABCG2 inhibition protocols in nonhuman primates resulting in pronounced increases in brain distribution of 11C-erlotinib. For patients with brain tumors, such inhibition protocols may ultimately be applied to create more effective treatments using drugs that undergo efflux transport at the BBB VSports最新版本. .

Keywords: P-glycoprotein; blood–brain barrier; brain metastasis; breast cancer resistance protein; erlotinib V体育平台登录. .

PubMed Disclaimer

MeSH terms

Substances